Our commitment to new medicines

ViiV Healthcare has already signed a Research Alliance Agreement with GSK and Pfizer under which it will invest in research and development into HIV medicines being conducted by both companies and will have exclusive rights of first negotiation in relation to any new HIV-related medicine developed by either GSK or Pfizer.

Our clear focus is to invest in research and development of innovative HIV treatments and formulations that improve adherence and overcome resistance to the virus.

© 2009 ViiV Healthcare group of companies. All rights reserved